<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563287</url>
  </required_header>
  <id_info>
    <org_study_id>NUDROBE</org_study_id>
    <nct_id>NCT03563287</nct_id>
  </id_info>
  <brief_title>Effects of LRYGB on Pharmacokinetics of Nine CYP Probe Drugs</brief_title>
  <official_title>Altered Metabolism of Nutrients and Drugs in Obesity and After Obesity Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Eastern Finland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Diabetes Research Foundation, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Finnish Cultural Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academy of Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Eastern Finland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to anatomical and physiological changes caused by the Roux-en-Y gastric bypass (RYGB)
      bariatric surgery, drug bioavailability after the surgery can be altered. Therefore,
      post-operative dose adjustment in these patients can be required.

      The aim of the study was to investigate the effects of laparoscopic Roux-en-Y gastric bypass
      (LRYGB) surgery on drug pharmacokinetics and cytochrome P450 (CYP) mediated metabolism using
      a cocktail of nine CYP probe drugs.

      The cocktail covers nine main CYP enzymes: melatonin (CYP1A2), nicotine (CYP2A6), bupropion
      (CYP2B6), repaglinide (CYP2C8), losartan (CYP2C9), omeprazole (CYP2C19/CYP3A4),
      dextromethorphan (CYP2D6), chlorzoxazone (CYP2E1), midazolam (CYP3A4).

      The changes in pharmacokinetic parameters of the drugs as well as modulation of the activity
      of CYPs are evaluated before and one year after LRYGB. In the study, the patients
      administering drug cocktail before surgery and 1 year after LRYGB are served as their own
      controls.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 27, 2012</start_date>
  <completion_date type="Actual">December 10, 2014</completion_date>
  <primary_completion_date type="Actual">December 10, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Probe cocktail drugs concentration-time profile in plasma and urine before LRYGB</measure>
    <time_frame>baseline, 1 hour, 2 hour, 4 hour and 6 hour</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Probe cocktail drugs concentration-time profile in plasma and urine 1 year after LRYGB</measure>
    <time_frame>baseline, 1 hour, 2 hour, 4 hour and 6 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic ratios of parent compounds and corresponding metabolites before LRYGB</measure>
    <time_frame>baseline, 1 hour, 2 hour, 4 hour and 6 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic ratios of parent compounds and corresponding metabolites 1 year after LRYGB</measure>
    <time_frame>baseline, 1 hour, 2 hour, 4 hour and 6 hour</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Obesity, Morbid</condition>
  <condition>Bariatric Surgery Candidate</condition>
  <arm_group>
    <arm_group_label>Phenotyping cocktail of 9 CYP probe drugs before surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenotyping cocktail of 9 CYP probe drugs 1 year after surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cocktail of nine CYP probe drugs</intervention_name>
    <description>Two equally loaded capsules containing:
Melatonin (2.0 mg) Nicotine (1.0 mg) Bupropion (37.5 mg) Repaglinide (0.25 mg) Losartan (12.5 mg) Omeprazole (10 mg) Chlorzoxazone (62.5 mg) Midazolam (1.85 mg) Dextromethorphan (30 mg) as an oral solution was administered separately after the capsules.</description>
    <arm_group_label>Phenotyping cocktail of 9 CYP probe drugs 1 year after surgery</arm_group_label>
    <arm_group_label>Phenotyping cocktail of 9 CYP probe drugs before surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI &gt; 40 kg/m2 or BMI 35-40 kg/m2 and a comorbidity or its risk factor, such as type 2
             diabetes, hypertension, sleep apnea, osteoarthritis of weight bearing joints or
             polycystic ovarian syndrome;

          -  previous conservative treatment for obesity had been proven to be ineffective;

          -  patients were assigned to undergo LRYGB surgery

          -  patients are able to give a written inform consent.

        Exclusion Criteria:

          -  smokers

          -  consuming alcohol more than 20 g per day were included in the study

          -  taking drugs which alter CYPs activity

          -  history of hypersensitivity to the drugs used in the cocktail
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Eastern Finland</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 8, 2018</study_first_submitted>
  <study_first_submitted_qc>June 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>June 19, 2018</last_update_submitted>
  <last_update_submitted_qc>June 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Eastern Finland</investigator_affiliation>
    <investigator_full_name>Jussi Pihlajam√§ki</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

